Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma
Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma
复制标题
DOI：
10.14670/hh-26.997
复制
发表时间：
2011-08-01
影响因子：
2
通讯作者：
von Bubnoff, Dagmar
中科院分区：
文献类型：
--
作者：
Kuales, Melanie Alice;Wenzel, Joerg;von Bubnoff, Dagmar
下唇鳞状细胞癌（SCC-LL）的患病率在全世界范围内不断增加。由抗原呈递细胞和/或肿瘤细胞表达吲哚胺2，3-双加氧酶（IDO）通过抑制T细胞介导的排斥反应导致肿瘤逃逸。本研究的目的是确定IDO在SCC-LL中的表达。通过免疫组织化学和免疫荧光分析，分析了47例SCC-LL中IDO表达，以及T细胞（CD 3）、髓样DC（S100，CD 11 c）、巨噬细胞（CD 68，CD 11 c）、朗格汉斯细胞（CD 1a，Langerin（CD 207））、浆细胞样DC（CD 123）和调节性T细胞（Foxp 3）标志物的表达。47个LLSCC中的12个标本含有表达IDO的细胞。IDO阳性与癌症相关浸润的强度密切相关（P=0.0007）。IDO阳性细胞正好沿着发展中的肿瘤和炎性浸润之间的边界。免疫荧光染色显示，SCC-LL中CD 11 c（+）S100（+）CD 68（-）树突状细胞（DCs）表达IDO。LL-SCC中的IDO表达可能有助于免疫逃逸和慢性炎症，从而促进癌症进展。抑制IDO可能是增强SCC-LL抗肿瘤免疫应答的治疗策略。
The prevalence of squamous cell carcinoma of the lower lip (SCC-LL) is increasing worlwide. The expression of the enzyme indoleamine 2,3-dioxygenase (IDO) by antigen-presenting cells and/or tumor cells leads to tumor escape by inhibiting T cell-mediated rejection responses. The aim of this study was to determine the expression of IDO in SCC-LL. IDO-expression was analyzed in 47 SCC-LL, together with the expression of markers of T-cells (CD3), myeloid DCs (S100, CD11c), macrophages (CD68, CD11c), Langerhans cells (CD1a, Langerin (CD207)), plasmacytoid DCs (CD123), and regulatory T cells (Foxp3) by immunohistochemistry and immunofluorescence analysis. Twelve specimens out of 47 LLSCCs contained cells that expressed IDO. IDO-positivity was strongly associated with the intensity of the cancer-associated infiltrate (P=0.0007). IDO-positive cells are located right along the border between the developing tumor and the inflammatory infiltrate. Immunofluorescence stainings showed that CD11c(+)S100(+)CD68(-) dendritic cells (DCs) express IDO in SCC-LL. IDO expression in LL-SCC may aid immune escape and chronic inflammation to promote cancer progression. Inhibition of IDO might be a therapeutic strategy to increase the anti-tumor immune response in SCC-LL.